AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Vertex, Inc.
Video analysis: VERX
All videosNo video analysis for this stock yet. Request one from our team.
News: VERX
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis
Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance.
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis and rare endocrine disorders.
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growth over the next few years, driven by new launches.
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area. Regeneron has successfully rebounded after facing biosimilar competition for a key growth driver, and it boasts several attractive pipeline candidates.
Vertex to Present at the Goldman Sachs Communacopia + Technology Conference
KING OF PRUSSIA, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026 at 1:05 PM Pacific Time.
